FDA Approves Atezolizumab (Tecentriq) for Treatment of Metastatic NSCLC

Share this content:
Atezolizumab (Tecentriq) is now approved by the FDA for the treatment of metastatic non-small cell lung cancer.
Atezolizumab (Tecentriq) is now approved by the FDA for the treatment of metastatic non-small cell lung cancer.

Atezolizumab (Tecentriq) is now approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung cancer (NSCLC), according to a press release.1

Based primarily on the results of the OAK (A Randomized Phase 3 Study of Atezolizumab Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy; ClinicalTrials.gov Identifier: NCT02008227) and POPLAR (A Randomized Phase 2 Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy; ClinicalTrials.gov Identifier: NCT01903993) studies, the drug is approved for patients whose diseases progress with platinum-based chemotherapies, or for those with EGFR or ALK actionable mutations.

RELATED: Study Reaffirms Osimertinib Activity in EGFR T790M-positive NSCLC

The OAK study showed about a 4-month average survival benefit over docetaxel (13.8 months compared to 9.6). Treatment was given to the 425 patients of each cohort.

Serious adverse events with atezolizumab include pneumonitis, hepatitis, colitis, glandular issues, neuropathy, meningitis, encephalitis, and eye inflammation.

Atezolizumab targets the PD-L1 protein, but is efficacious regardless of PD-L1 expression.

Reference

  1. FDA Approves Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer. Genentech website. https://www.gene.com/media/press-releases/14641/2016-10-18/fda-approves-genentechs-cancer-immunothe. Updated October 18, 2016. Accessed October 19, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters